Antibody Mediated Rejection clinical trials at UCSF
2 in progress, 1 open to eligible people
Felzartamab in Kidney Transplant Recipients With Late Antibody-Mediated Rejection (AMR)
open to eligible people ages 18-75
The main goal of this trial is to evaluate the efficacy of felzartamab compared to placebo in kidney transplant recipients diagnosed with late active or chronic active AMR.
San Francisco 5391959, California 5332921 and other locations
BIVV020 (SAR445088) n Prevention and Treatment of Antibody-mediated Rejection (AMR)
Sorry, in progress, not accepting new patients
Primary Objectives: - Cohort A: To evaluate the efficacy of BIVV020 in prevention of AMR - Cohort B: To evaluate the efficacy of BIVV020 in treatment of active AMR Secondary Objectives: - To assess the overall efficacy of BIVV020 in prevention or treatment of AMR - To characterize the safety and tolerability of BIVV020 in kidney transplant participants - To characterize the pharmacokinetic (PK) profile of BIVV020 in kidney transplant participants - To evaluate the immunogenicity of BIVV020
San Francisco 5391959, California 5332921 and other locations
Our lead scientists for Antibody Mediated Rejection research studies include Puneet Sood.
Last updated: